Abstract Details

Title An Open Label Study of Poly-MVA to Treat Fatigue in ALS

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 11-005

Background

Fatigue is a common and debilitating symptom among ALS patients, which is characterized by reversible motor weakness and whole-body tiredness that is only partially relieved by rest. The effectiveness of pharmacological or non-pharmacological treatments for fatigue in ALS is not yet established.

Objective

The objective of this study was to assess the safety of Poly-MVA (a dietary supplement containing a proprietary blend of Lipoic Acid Mineral Complex) in patients with ALS as well as monitoring effectiveness in improving fatigue.

Design/Methods This was an open label non-randomized, non-blinded study. We recruited nine ALS patients (clinically definite based on revised El-Escorial criteria) from October 2020 to December 2020. Poly-MVA was administered with the dose of two teaspoons twice a day (morning and afternoon) for six months. Symptoms of quality of life and side effects were monitored.

Results Age range was 59-74 years. There were 7 men, 2 women. 8 were limb onset and one was bulbar onset. There were six patients that are on either riluzole and edaravone and just one patient was not taking either of the medications. ALSQ-50 had a baseline score of 7.19 and at the one month mark had an improvement to 8.1 in the ALSQ-50 score. Overall, The data shows that there was not a decrease in quality of life, fatigue, and depression during the six month trial, in fact there was a significant improvement in these measurements at the first and three month time mark.

Conclusions This pilot study shows that Poly-MVA is safe and well-tolerated among ALS patients. Overall, the data showed that patients did not have regression in the quality of life, fatigue, and depression over the six month trial period and showed to have improvement in these factors for the first 3 months of being on the supplement.

Authors/Disclosures
Amer Avdagic PRESENTER	Mr. Avdagic has nothing to disclose.
Tejas R. Mehta, MD	Dr. Mehta has nothing to disclose.
	No disclosure on file
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group)	Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.